Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319)

The activity of didemnin B, a natural product derived from the Caribbean Tu nic was assessed in 16 patients with Glioblastoma multiforme. Didemnin B wa s administered intravenously by a short infusion at a dose of 4.3 mg/m(2) a nd subsequently escalated to 6.3 mg/m(2). No anti-tumor activity was observ ed. Toxicity consisted of fatigue, weakness, stomatitis, mild blood count c hanges, nausea and vomiting and occasional fever. Based on these results fu rther studies with didemnin B in patients with Glioblastoma multiforme are not recommended.